Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

SDP exercises option to acquire five Roivant divisions; forms Sumitovant to run them

Executive Summary

Sumitomo Dainippon Pharma Co. Ltd. (SDP) paid $3bn in cash to exercise its previously announced option to acquire five Roivant Sciences Inc. biopharmaceutical divisions (known as vants). The five companies--Altavant Sciences Inc. (rare respiratory diseases), Enzyvant Sciences Ltd. (rare immunodeficiency diseases), Myovant Sciences Ltd. (women's health and prostate cancer), Urovant Sciences Ltd. (urinary disorders), and Spirovant Sciences Ltd. (gene therapies for cystic fibrosis)--will operate under a newly formed, 50.2% wholly owned SDP subsidiary Sumitovant Biopharma Ltd., run by Roivant's Myrtle Potter as CEO.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Full Acquisition
    • Payment Includes Cash for Equity

Related Companies